ストックスクリーナーアプリを入手
1.34
0.75%
0.01
アフターアワーズ：
1.33
-0.01
-0.75%
Soligenix Inc (SNGX) 最新ニュース
Soligenix (NASDAQ: SNGX) Advances Ricin Vaccine amid Toxin Threat - Digital Journal
SNGX: Positive Results for Phase 2a Trial in Psoriasis - Research Tree
Soligenix publishes promising Phase 2a data for SGX945 in Behcet's Disease - Indian Pharma Post
Gains Recap: Will Soligenix Inc. (DOA0) stock issue positive guidanceJuly 2025 Market Mood & Free Verified High Yield Trade Plans - Улправда
Is Soligenix Inc. stock cheap at current valuationQuarterly Profit Summary & Smart Money Movement Tracker - Улправда
Will Soligenix Inc. (DOA0) stock issue positive guidanceJuly 2025 Summary & Growth Focused Entry Point Reports - Улправда
Institution Moves: Will Soligenix Inc. (DOA0) stock beat Nasdaq index returnsJuly 2025 PostEarnings & Daily Profit Maximizing Trade Tips - DonanımHaber
How Soligenix Inc. stock benefits from strong dollarJuly 2025 Pullbacks & Capital Efficiency Focused Ideas - DonanımHaber
Soligenix (NASDAQ: SNGX) Publishes Positive Phase 2a SGX945 Data in Behcet's Disease - Digital Journal
Soligenix reports positive results from SGX945 trial for Behçet’s disease By Investing.com - Investing.com Nigeria
Soligenix (NASDAQ: SNGX) Publishes Positive Phase 2a SGX945 Data in Behçet’s Disease - Barchart.com
Soligenix, Inc. Announces Positive Clinical Results from Phase 2 Trial of Sgx945 for the Treatment of Behcet's Disease Published in Rheumatology - marketscreener.com
Soligenix shares jump on encouraging data for Behçet’s disease therapy - MSN
Soligenix stock rises after positive Behçet’s Disease treatment data By Investing.com - Investing.com Nigeria
Soligenix stock rises after positive Behçet’s Disease treatment data - Investing.com India
Soligenix (SNGX) Shows Promising Results in Phase 2a Behcet's Di - GuruFocus
Soligenix reports positive results from SGX945 trial for Behçet’s disease - Investing.com
Positive Clinical Results from Phase 2 Trial of SGX945 for the T - GuruFocus
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behcet's Disease Published in Rheumatology (Oxford) - Finviz
Positive clinical results from phase 2 trial of SGX945 - marketscreener.com
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) - Fidelity
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) – Company AnnouncementFT.com - Financial Times
Market Recap: How strong is Soligenix Inc. stock balance sheetChart Signals & Verified Swing Trading Watchlists - Улправда
Soligenix (NASDAQ: SNGX) Reports Extended Phase 2a Results for SGX302 Gel in Mild-to-Moderate Psoriasis - Digital Journal
Soligenix reports positive results from psoriasis gel treatment trial By Investing.com - Investing.com Nigeria
Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel - Benzinga
Soligenix Announces Top-line Results of the Phase 2a Study of SG - GuruFocus
Soligenix reports positive results from psoriasis gel treatment trial - Investing.com
Soligenix announces top-line results of the phase 2a study of SGX302 - marketscreener.com
Soligenix (SNGX) Reports Promising Phase 2a Results for Psoriasis Treatment - GuruFocus
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis – Company AnnouncementFT.com - Financial Times
What drives Soligenix Inc DOA0 stock priceFederal Reserve Announcements & Small Investment Growth Plans - earlytimes.in
[Form 4] SOLIGENIX, INC. Insider Trading Activity - Stock Titan
Soligenix (NASDAQ: SNGX) awards CFO 100,000 options at $ 1.63 strike - Stock Titan
Soligenix (NASDAQ: SNGX) Featured in NetworkNewsAudio APR on Urgent Need for Rare Disease Therapies - Digital Journal
Soligenix’s HyBryte Therapy Advances as Rare Disease Treatment Gap Grows - citybuzz
NetworkNewsAudio Announces Audio Press Release (APR) on Final Confirmatory Clinical Study Being Done for Treatment of Rare Disease - The Manila Times
NetworkNewsAudio Announces Audio Press Release (APR) on - GlobeNewswire
Soligenix (NASDAQ: SNGX) Receives Strong Vote of Confidence from Zacks Report Despite Muted Market Response to Clinical Milestone - Digital Journal
Soligenix (NASDAQ: SNGX) Featured in BioMedWire Editorial on Rare Disease Therapies - Digital Journal
Soligenix Featured in Editorial on Growing Need for Rare Disease Therapies - citybuzz
Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad - GlobeNewswire
Why Soligenix Inc. (DOA0) stock signals breakout potentialInflation Watch & Fast Exit and Entry Strategy Plans - Newser
How Soligenix Inc. (DOA) stock expands through international marketsStop Loss & Weekly High Return Opportunities - Newser
Is Soligenix Inc. (DOA0) stock cheap vs fundamentalsTrade Volume Report & Risk Adjusted Swing Trade Ideas - Newser
Is Soligenix Inc. stock a buy before product launchesWeekly Trend Summary & Expert Verified Stock Movement Alerts - Newser
Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations - GlobeNewswire
Is Soligenix Inc. (DOA) stock in buy zone after pullback2025 Volume Leaders & Low Drawdown Momentum Trade Ideas - Newser
Cutaneous T-cell Lymphoma Market Expected to Experience Major Growth by 2032, According to DelveInsight | Innate Pharma, Galderma R&D, Kyowa Kirin, Citius Pharma, Soligenix, 4SC AG, oligenix, Ligand - Barchart.com
Soligenix’s HyBryte Development Intersects with National Rare Disease Policy Needs - citybuzz
0.90%
大文字化:
|
ボリューム (24 時間):